U.S. regulators OK first new Alzheimer’s drug in nearly 20 years, against the advice of their own outside experts

More Articles:

• September 13

  Stocks Rally Friday, Notch Weekly Gains as Volatility Index Plunges

• September 15

  Knudsen Enters Paramount-Warner Antitrust Fight

• September 18

  Forstag’s Lobbying Record Draws Scrutiny in MT-01 Race

• September 17

  Big Sky Broadcasting to Acquire Two Missoula-Area Radio Stations

• September 20

  Sheehy’s Air Traffic Safety Bill Advances Through Senate Committee

• September 15

  Ballot language for Idaho’s abortion vote still not right